Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

about

Cancer vaccine: learning lessons from immune checkpoint inhibitors.Current Strategies to Enhance Anti-Tumour Immunity.Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer

P2860

Q49260236-8E6FA5D5-889F-4DDD-AEB4-473C9B1890A6 Q52344613-64CE0703-E1B2-401D-9F36-37528B8A299B Q56892705-24E6D305-114F-492D-9A44-79ED011734C1

P2860

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

Item

http://www.wikidata.org/entity/Q38730989

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Tumor immunotherapy: drug-indu ...... immune checkpoint inhibitors.

@en

type

Item

label

Tumor immunotherapy: drug-indu ...... immune checkpoint inhibitors.

@en

prefLabel

Tumor immunotherapy: drug-indu ...... immune checkpoint inhibitors.

@en

P1476

Tumor immunotherapy: drug-indu ...... immune checkpoint inhibitors.

@en

P2093

Angelo Aquino

http://www.w3.org/2001/XMLSchema#string

Anna Giuliani

http://www.w3.org/2001/XMLSchema#string

Enzo Bonmassar

http://www.w3.org/2001/XMLSchema#string

Francesco Torino

http://www.w3.org/2001/XMLSchema#string

Maria Pia Fuggetta

http://www.w3.org/2001/XMLSchema#string

Mario Roselli

http://www.w3.org/2001/XMLSchema#string

Stefania D'Atri

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The PD-1 pathway in tolerance and autoimmunity

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Myeloid-derived suppressor cells: linking inflammation and cancer

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

P304

41641-41669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.18632/ONCOTARGET.16335

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ornella Franzese

P5008

ScienceSource

P577

2017-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28404974

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

triazene

P932

5522228

http://www.w3.org/2001/XMLSchema#string

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

about

P2860

P2860

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932